InflaRx N.V.
NASDAQ: IFRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Niels C. Riedemann
- Employees
- 74
- Headquarters
- Jena, Germany
- IPO year
- 2017
- Market cap
- $139.4M
- Website
- https://www.inflarx.de
Loading IFRX…
Loading profile data…Frequently asked questions about IFRX
What does InflaRx N.V. (IFRX) do?
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory...
Where does IFRX trade?
InflaRx N.V. (IFRX) trades on the NASDAQ Global Select.
What sector is IFRX in?
InflaRx N.V. (IFRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of InflaRx N.V.?
Niels C. Riedemann is the chief executive officer of InflaRx N.V. (IFRX).
Where is InflaRx N.V. headquartered?
InflaRx N.V. is headquartered in Germany.
Does IFRX pay a dividend?
InflaRx N.V. (IFRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IFRX go public?
InflaRx N.V. (IFRX) completed its initial public offering in 2017.